

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
25 May 2023 (25.05.2023)



(10) International Publication Number
WO 2023/091414 A1

(51) International Patent Classification:

A61K 31/496 (2006.01) A61P 7/06 (2006.01)

A61K 31/5025 (2006.01)

(21) International Application Number:

PCT/US2022/049969

(22) International Filing Date:

15 November 2022 (15.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/280,069 16 November 2021 (16.11.2021) US

63/357,240 30 June 2022 (30.06.2022) US

(71) Applicant: AGIOS PHARMACEUTICALS, INC.

[US/US]; 88 Sidney Street, Cambridge, MA 02139 (US).

(72) Inventors: BEYNON, Vanessa; 39 Rockmont Road, Ar-

lington, MA 02474 (US). BHATIA, Suman, Joy; 88 Syd-

ney Street, Cambridge, MA 02139 (US). DAI, Xiaoshu;

88 Sidney Street, Cambridge, MA 02139 (US). DANG,

Lenny; 88 Sidney Street, Cambridge, MA 02139 (US).

DIBACCO, Melissa, L.; 88 Sidney Street, Cambridge,

MA 02139 (US). IYER, Varsha, V.; c/o Agios Pharma-

ceuticals, Inc., 88 Sidney Street, Cambridge, MA 02139

(US). KUNG, Charles; 39 Rockmont Road, Arlington,

MA 02474 (US). LYNCH, Megan; 88 Sidney Street,

Cambridge, MA 02139 (US). QIPING YIN, Ophelia; 88

Sidney Street, Cambridge, MA 02139 (US). URBSTON-

AITIS, Rolandas; c/o Agios Pharmaceuticals, Inc., 88 Sid-

ney Street, Cambridge, MA 02139 (US). XIAO, Zhen; 88

Sidney Street, Cambridge, MA 02139 (US).

(74) Agent: DEGRAZIA, Michael, J. et al.; McCarter & Eng-

lish, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,

KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,

LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,

NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,

RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,

ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,

TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))

WO 2023/091414 A1

(54) Title: COMPOUNDS FOR TREATING MDS-ASSOCIATED ANEMIAS AND OTHER CONDITIONS

(57) Abstract: Provided herein is the use of certain pyruvate kinase activators or pharmaceutically acceptable salts or compositions thereof for treating MDS -associated anemia and other conditions.